Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Status:
Terminated

Trial end date:
2017-06-22

Target enrollment:

Participant gender:

The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.

Phase 1/Phase 2

Gilead Sciences

Vincristine